A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.

Clinical outcome in ovarian carcinoma is predicted by progesterone receptor status, indicating an endocrine aspect to this disease. Peripheral leucocyte genomic DNAs were obtained from 41 patients with primary ovarian carcinoma and 83 controls from Ireland, as well as from 26 primary ovarian carcino...

Descripción completa

Detalles Bibliográficos
Autores principales: McKenna, N. J., Kieback, D. G., Carney, D. N., Fanning, M., McLinden, J., Headon, D. R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033643/
https://www.ncbi.nlm.nih.gov/pubmed/7880723
_version_ 1782136881906974720
author McKenna, N. J.
Kieback, D. G.
Carney, D. N.
Fanning, M.
McLinden, J.
Headon, D. R.
author_facet McKenna, N. J.
Kieback, D. G.
Carney, D. N.
Fanning, M.
McLinden, J.
Headon, D. R.
author_sort McKenna, N. J.
collection PubMed
description Clinical outcome in ovarian carcinoma is predicted by progesterone receptor status, indicating an endocrine aspect to this disease. Peripheral leucocyte genomic DNAs were obtained from 41 patients with primary ovarian carcinoma and 83 controls from Ireland, as well as from 26 primary ovarian carcinoma patients and 101 controls in Germany. Southern analysis using a human progesterone receptor (hPR) cDNA probe identified a germline TaqI restriction fragment length polymorphism (RFLP) defined by two alleles: T1, represented by a 2.7 kb fragment; and T2, represented by a 1.9 kb fragment and characterised by an additional TaqI restriction site with respect to T1. An over-representation of T2 in ovarian cancer patients compared with controls in the pooled Irish/German population (P < 0.025) was observed. A difference (P < 0.02) in the distribution of the RFLP genotypes between Irish and German control populations was also observed. The allele distributions could not be shown to differ significantly from Hardy-Weinberg distribution in any subgroup. Using hPR cDNA region-specific probes, the extra TaqI restriction site was mapped to intron G of the hPR gene. IMAGES:
format Text
id pubmed-2033643
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20336432009-09-10 A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. McKenna, N. J. Kieback, D. G. Carney, D. N. Fanning, M. McLinden, J. Headon, D. R. Br J Cancer Research Article Clinical outcome in ovarian carcinoma is predicted by progesterone receptor status, indicating an endocrine aspect to this disease. Peripheral leucocyte genomic DNAs were obtained from 41 patients with primary ovarian carcinoma and 83 controls from Ireland, as well as from 26 primary ovarian carcinoma patients and 101 controls in Germany. Southern analysis using a human progesterone receptor (hPR) cDNA probe identified a germline TaqI restriction fragment length polymorphism (RFLP) defined by two alleles: T1, represented by a 2.7 kb fragment; and T2, represented by a 1.9 kb fragment and characterised by an additional TaqI restriction site with respect to T1. An over-representation of T2 in ovarian cancer patients compared with controls in the pooled Irish/German population (P < 0.025) was observed. A difference (P < 0.02) in the distribution of the RFLP genotypes between Irish and German control populations was also observed. The allele distributions could not be shown to differ significantly from Hardy-Weinberg distribution in any subgroup. Using hPR cDNA region-specific probes, the extra TaqI restriction site was mapped to intron G of the hPR gene. IMAGES: Nature Publishing Group 1995-03 /pmc/articles/PMC2033643/ /pubmed/7880723 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
McKenna, N. J.
Kieback, D. G.
Carney, D. N.
Fanning, M.
McLinden, J.
Headon, D. R.
A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.
title A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.
title_full A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.
title_fullStr A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.
title_full_unstemmed A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.
title_short A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.
title_sort germline taqi restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033643/
https://www.ncbi.nlm.nih.gov/pubmed/7880723
work_keys_str_mv AT mckennanj agermlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT kiebackdg agermlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT carneydn agermlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT fanningm agermlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT mclindenj agermlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT headondr agermlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT mckennanj germlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT kiebackdg germlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT carneydn germlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT fanningm germlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT mclindenj germlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma
AT headondr germlinetaqirestrictionfragmentlengthpolymorphismintheprogesteronereceptorgeneinovariancarcinoma

Ejemplares similares